LFMDP
LifeMD, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$23.50
+0.05%Aug 5, 2026, 23:45 UTC
LifeMD reported second quarter 2026 revenue of $47.3 million and an adjusted EBITDA loss of approximately $3.5 million, improving about 21% sequentially.
Jun 23, 2026, 12:00 UTC
LifeMD, Inc. declared a quarterly cash dividend of $0.5546875 per share on its Series A Cumulative Perpetual Preferred Stock, payable on July 15, 2026 to holders of record on July 3, 2026.
Source:Jun 22, 2026, 12:00 UTC
LifeMD entered into an exclusive collaboration with a pharmaceutical manufacturer to launch a direct-to-patient self-pay program for XYOSTED (testosterone enanthate) injection, launching in July 2026 in 37 states.
Source: